The flagship clinical reference for ACUTESHIELD VITALITY™ centers on high-potency Nattokinase (delivered at 6,000 IU/FU in the liposomal formula; 10,800 IU equivalent in study), supported by one of the largest relevant human studies in the nattokinase literature.

Primary Study: Chen et al. (2022) – Effective Management of Atherosclerosis Progress and Hyperlipidemia with Nattokinase

Published: Frontiers in Cardiovascular Medicine (2022) 

Participants: 1,062 adults (average age ~67.5 years, range 63–85) with hyperlipidemia, early carotid atherosclerosis/plaque, or both. Retrospective clinical analysis conducted in China. 

Duration: 12 months 

Dosage: Primary group received 10,800 FU/day of standard ingredients (3,600 FU three times daily). A lower-dose comparison group received 3,600 FU/day.  10,800 IU of standard ingredients = 500 mg. The liposomal equivalent is 200-250 mg.

Key Measurements: Blood lipid panel (TC, TG, LDL-C, HDL-C) + carotid ultrasound for intima-media thickness (IMT) and plaque size/area.

Major Results (High-Dose 10,800 FU/day Group)

Arterial Plaque & Vessel Health (Ultrasound Findings): Average 36% reduction in carotid plaque area/size. Average ~22% reduction (or 21.7%) in carotid artery intima-media thickness (CCA-IMT). 

Improvement rates:  66.5% of participants showed reduction in carotid plaque size. 

77.7% showed reduction in arterial wall thickness (IMT).

Overall improvement rates across key vascular metrics ranged from 66.5% to 95.4%. 

The lower dose (3,600 FU/day) was largely ineffective for plaque and IMT improvements.

Lipid Profile Improvements:

Total Cholesterol (TC): 15.9% average reduction — improved in 95.4% of participants. 

Triglycerides (TG): 15.3–15.7% average reduction — improved in 85.2% of participants. 

LDL-C: 18.1% average reduction — improved in 84.3% of participants. 

HDL-C: 15.8% average increase — improved in 89.1% of participants.

These changes were statistically significant (p < 0.01) compared to baseline.

Safety: No obvious adverse reactions related to nattokinase use were observed across the entire study cohort. Efficacy was consistent between male and female participants. Greater benefits were noted in subgroups who exercised regularly, quit smoking/alcohol, or had higher BMI in some analyses. Synergistic effects were observed with co-administration of Vitamin K2 (highly relevant since ACUTESHIELD VITALITY™ includes K2-MK7).

Supporting Context from Related Nattokinase Research

A separate smaller study using 6,000 FU/day for 26 weeks also demonstrated significant reductions in carotid IMT and plaque size (36.6% plaque reduction vs. 11.5% with statins in that comparison), reinforcing dose-dependent benefits in the range used in ACUTESHIELD VITALITY™.

Relevance to ACUTESHIELD VITALITY™

The formula delivers liposomal Nattokinase at 6,000 IU (10,800 IU standard) alongside synergistic partners like Vitamin K2-MK7 (for proper calcium directing and enhanced vascular benefits), L-Citrulline, Resveratrol, Astaxanthin, and the full liposomal Life Protection & Energy matrix. This combination is designed to amplify the vascular clearance, lipid support, nitric oxide, and anti-inflammatory effects observed in the clinical data.

While the full ACUTESHIELD formula itself has not yet undergone a dedicated multi-ingredient clinical trial, its Nattokinase component is dosed at a clinically relevant level, and the supporting ingredients (PQQ, NAD, CoQ10, Curcumin, etc.) have extensive individual research backing their roles in mitochondrial health, oxidative stress reduction, and metabolic support.

Investor Note: This large-scale human data provides credible, ultrasound-verified storytelling for marketing (e.g., “Clinically shown plaque and IMT improvements in over 1,000 participants”) while offering a strong foundation for future product-specific trials, physician detailing, and differentiation in the longevity market. The dose-response finding (higher dose superior) further supports premium positioning.

Citation

Chen H, Chen J, Zhang F, Li Y, Wang R, Zheng Q, Zhang X, Zeng J, Xu F, Lin Y. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Front Cardiovasc Med. 2022 Aug 22;9:964977. doi: 10.3389/fcvm.2022.964977. Erratum in: Front Cardiovasc Med. 2022 Dec 05;9:1076420. doi: 10.3389/fcvm.2022.1076420. PMID: 36072877; PMCID: PMC9441630.

FDA Disclaimer:

The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product. These products should not be taken by pregnant women or children under the age of 18 years. The Federal Food and Drug Act require this notice.